Key Highlights
- On April 1, Oklo’s top three executives—CEO Jacob DeWitte, COO Caroline Cochran, and CFO Richard Bealmear—collectively sold more than $21M worth of shares through prearranged trading plans.
- DeWitte has maintained a consistent selling pattern dating back to January, disposing of shares at prices spanning from approximately $100 to $50.
- CNBC’s Jim Cramer characterized Oklo as lacking “very little prospects for making any money any time in the future” and dismissed it as “not a commercial enterprise.”
- The company’s recent quarterly results showed a loss per share of -$0.27, significantly worse than Wall Street’s forecast of -$0.17.
- Despite maintaining a “Moderate Buy” consensus, analysts have progressively lowered their price targets, with the current average standing at $84.30.
Oklo’s executive leadership executed substantial stock sales totaling more than $21 million on April 1, 2026, through previously established Rule 10b5-1 trading arrangements.
Chief Executive Officer Jacob DeWitte divested shares at average prices spanning $48.41 to $51.20, generating proceeds of $10,069,852. Following this transaction, his direct ownership stands at 691,533 Class A shares, with indirect holdings exceeding 20 million shares.
Co-founder and Chief Operating Officer Caroline Cochran executed transactions totaling $10,069,852, with share prices between approximately $47.99 and $51.79. Her direct ownership following the sale is 658,039 shares.
Chief Financial Officer Richard Bealmear disposed of 16,342 shares at $51.08 each, collecting $834,749. His remaining direct holdings total 386,008 Class A shares.
While all three transactions occurred under pre-established 10b5-1 trading plans—designed to shield executives from insider trading allegations—they represent significant liquidity events for the company’s leadership team.
DeWitte’s selling activity extends well beyond the April 1 transactions. Since the beginning of January, he has systematically reduced his position through multiple transactions at prices including approximately $112, $75, and $63 per share. The cumulative proceeds from these sales over recent months total tens of millions of dollars.
The April 1 sale alone—comprising 200,000 shares across two separate transactions—represented a 17.58% decrease in his directly held position.
Jim Cramer’s Bearish Assessment
The substantial insider selling coincides with sharply critical commentary from CNBC’s Jim Cramer. During a recent broadcast, Cramer offered a blunt assessment: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
This wasn’t Cramer’s first time expressing skepticism about the company. Back in January, he characterized Oklo as “not a commercial enterprise” and suggested that while nuclear energy holds promise, established companies like GE Vernova—which operate commercially viable businesses—represent superior investment opportunities compared to Oklo at this stage.
Financial Performance Falls Short of Expectations
From a financial perspective, Oklo disappointed investors with its latest quarterly results, posting a loss of $0.27 per share compared to analyst expectations of -$0.17—a miss of $0.10.
Despite the disappointing results, Wall Street analysts maintain a generally optimistic outlook, though their price targets have undergone meaningful revisions. UBS reduced its target from $95 to $60 while assigning a neutral rating. Needham slashed its target from $135 to $73, and Canaccord lowered its estimate from $175 to $125. Cantor Fitzgerald maintained its overweight rating alongside a $122 price target.
The consensus analyst price target currently stands at $84.30, with an overall “Moderate Buy” rating. The rating breakdown includes two Strong Buy recommendations, nine Buy ratings, six Hold ratings, and two Sell ratings.
Oklo’s shares have traded within a 12-month range of $17.42 to $193.84. The stock’s 50-day moving average sits at $64.62, while the 200-day moving average stands at $93.16.
